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Abstract
Rationale Aggression and irritability are notable psychiatric side effects of anabolic-androgenic steroid (AAS) use. However, no
previous study has systematically reviewed and quantitatively synthesized effects reported by experimental studies on this topic.
Objective We conducted a systematic review andmeta-analysis of randomized controlled trials (RCTs) investigating the effect of
AAS administration on self-reported and observer-reported aggression.
Methods Twelve RCTs comprising a total of 562 healthy males were identified through systematic searches of MEDLINE,
PsycInfo, ISI Web of Science, ProQuest, Google Scholar, and the Cochrane Library.
Results After excluding one outlier, AAS administration was associated with an increase in self-reported aggression under a
random-effects model, albeit small (Hedges’ g = 0.171, 95% CI: 0.029–0.312, k = 11, p = .018), and when restricting the analysis
to the effect of acute AAS administration on self-reported aggression under a fixed-effect model (g = 0.291, 95% CI: 0.014–
0.524, p = .014). However, the above effects were neither replicated in the analysis of observer-reported aggression nor after
restricting the analysis to the effects of the administration of higher (over 500 mg) and long-term (3 days to 14 weeks) doses.
Conclusions The present meta-analysis provides evidence of an increase, although small, in self-reported aggression in healthy
males following AAS administration in RCTs. Ecologically rational RCTs are warranted to better explore the effect of AAS
administration on aggression in humans.
Keywords Anabolic-androgenic steroids . Aggression .Meta-analysis . Randomized controlled trial
Introduction
Anabolic-androgenic steroids (AAS) are a family of hormones
comprising the androgen hormone testosterone as well as its
synthetic derivatives (Kanayama and Pope 2018). Use of AAS
was historically associated with weightlifters and later with
professional bodybuilders and elite athletes in various sports.
Since the 1980s, use of AAS has gradually spread to
recreational athletes as well as the general population
(Pope and Kanayama 2012). Use of AAS normally com-
prises long-term administration of supraphysiological
doses often 10–100 times the natural production or thera-
peutic doses of androgens (Kanayama et al. 2013). A meta-
analysis on the global prevalence of AAS use indicated that
3.3% of the world’s population has used AAS at least once
with use being more frequent among males (6.4%) com-
pared to (1.6%) females (Sagoe et al. 2014b; Sagoe and
Pallesen 2018).
Despite benefits such as increased muscle growth, im-
proved body image, and enhanced sports performance
(Evans 2004; Sagoe et al. 2014a; Smit et al. 2020a), hu-
man case studies, surveys, and experimental studies sug-
gest that AAS induce a plethora of physical and psycho-
logical adverse side effects. Cardiovascular disorders, par-
ticularly cardiomyopathy, are major physical side effects
of AAS use (Baggish et al. 2017). Other somatic side
effects of AAS include hypertension, sleep abnormalities,
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immunological dysregulation, decreased libido in males,
and hirsutism and clitoromegaly in females (Bensoussan
and Anderson 2019; Ganesan et al. 2020). Notable psycho-
logical side effects comprise manic and depressive symp-
toms as well as psychotic symptoms (Brower 2009;
Kanayama et al. 2020). Human case studies, surveys, and
experimental studies further suggest that AAS induce a
plethora of symptoms such as irritability and unprovoked
aggression sometimes referred to as “roid rage” or “steroid
rage” (Nelson 1989; Pope and Katz 1987; Taylor 1987;
Tragger 1988). Experimental animal studies show consis-
tently that injections of AAS increase aggression (Clark and
Henderson 2003; Lumia et al. 1994). For human studies,
cross-sectional (Ganson and Cadet 2019; Pereira et al.
2019), case-control (Klötz et al. 2007; Lundholm et al.
2010; Thiblin et al. 2015), and longitudinal (Beaver et al.
2008) researches indicate a positive relationship between
AAS use and aggression. However, results from human
placebo-controlled randomized studies show an inconsis-
tent association between AAS administration and aggres-
sion comprising negative (Björkqvist et al. 1994), positive
(Panagiotidis et al. 2017; Wagels et al. 2018), and non-
significant findings (Tricker et al. 1996).
Most previous reviews on this topic are merely narrative
(Haug et al. 2004; Huo et al. 2016; Johnson et al. 2013).
Additionally, a recent review (Geniole et al. 2020) on this
topic lacks some studies (Anderson et al. 1992; Björkqvist
et al. 1994; Su et al. 1993; Tricker et al. 1996). Hence, a
comprehensive systematic review quantifying findings on
the topic is overdue in line with the merit of meta-analyses
in science and evidence-based medicine (Murad et al.
2016). Against this backdrop, we conducted a systematic
review and meta-analysis of randomized controlled trials
(RCTs) examining the effect of AAS administration on




Systematic literature searches were conducted in MEDLINE,
PsycInfo, ISI Web of Science, ProQuest, Google Scholar, and
Cochrane Library. There was no time constraint for the search.
Keywords for AASwere combined with keywords for aggres-
sion. An overview of the keywords and search strategy can be
found in Appendix A in the Supplementary information. The
latest systematic literature search was conducted on 31
December 2019 followed by additional ad hoc searches to
ensure comprehensiveness. The search and selection process
are presented in Fig. 1.
Inclusion criteria and data extraction
Included studies were as follows: (1) RCTs, (2) investi-
gating the effects of AAS administration on aggression in
healthy persons, (3) based on valid aggression measures,
and (4) published in English. The first author (RC) inde-
pendently conducted the search and selection of articles
based on the aforementioned criteria. Using a standard-
ized data extraction form, the first and last (RC and DS)
authors independently extracted the following data from
the identified studies: study authors, country, design (e.g.,
double-blind), sample type (e.g., healthy males), sample
size, age (range, M ± SD), study groups (e.g., placebo
group), AAS type, AAS dose, AAS administration mode
(e.g., injection), study duration, assessment type (e.g.,
self-report), aggression measure, results, and risk of bias
(see Table 1). Furthermore, the testosterone levels both at
baseline and post-administration for each study are shown
in Table 2. The two authors reached consensus in cases of
discrepant extractions through discussions, with the in-
volvement of the second author SP) when necessary. We
also contacted corresponding authors or, when unavail-
able, coauthors via email for missing information.
Statistical analysis
We first investigated the overall effect of AAS administration
on self-reported aggression using a random-effects model.
AAS users typically administer supraphysiologic doses of
AAS for 4 to 28 weeks (Kanayama et al. 2013; Copeland
et al. 2000). We therefore subsequently pooled studies in
which higher doses (over 500 mg) of AAS were administered
for the examination of the effect of high-dose AAS adminis-
tration on self-reported aggression (O’Connor et al. 2004;
Pope et al. 2000; Su et al. 1993; Tricker et al. 1996; Yates
et al. 1999). Furthermore, we pooled studies in which AAS
were administered over longer periods (i.e., 3 days to 14
weeks: Anderson et al. 1992; Cueva et al. 2017; O’Connor
et al. 2002; O’Connor et al. 2004; Pope et al. 2000; Su et al.
1993; Yates et al. 1999) as well as studies investigating acute
AAS effects (Carré et al. 2017; Dreher et al. 2016;
Panagiotidis et al. 2017; Tricker et al. 1996). Due to the low
number of studies administering higher doses (k = 5) or in-
vestigating acute AAS effects (k = 4), a fixed-effect model
was used for these analyses (Borenstein 2009). Moreover,
we conducted a meta-regression analysis to elucidate a po-
tential dose-response association, regressing AAS dose
(mg) on self-reported aggression. Finally, we investigated
the overall effect of AAS administration on observer-
reported aggression using a fixed-effect model due to the
low number of studies (k = 3: O’Connor et al. 2004; Tricker
et al. 1996; Yates et al. 1999).
Psychopharmacology
Some studies used multiple aggression measures and re-
ported multiple aggression scores (O’Connor et al. 2002,
2004; Panagiotidis et al. 2017; Pope et al. 2000; Su et al.
1993). In these cases, we set the correlation between aggres-
sion measures to 0.60 (Diamond and Magaletta 2006;
O’Connor et al. 2001) to provide the best estimates of
between-study variance and corresponding confidence inter-
vals (Gleser and Olkin 2009; Marín-Martínez and Sánchez-
Meca 1999). For crossover studies (O’Connor et al. 2004;
Pope et al. 2000; Su et al. 1993; Yates et al. 1999), we used
an average correlation of 0.50 between aggression measures
over time to provide optimal effect size estimates (Krahé and
Möller 2010). Effects were estimated as Hedges’ g, where
0.20 is considered small, 0.50 moderate, and 0.80 as large
effect sizes, respectively (Hedges and Olkin 2014). For studies
including a passive control group (e.g., no intervention), a
placebo group, and a treatment group (Björkqvist et al.
1994), data from the placebo and treatment groups were used
to estimate meaningful relative-effect estimates (Karlsson and
Bergmark 2015; Magill and Longabaugh 2013). Effect sizes
were calculated by pooling post-intervention mean and stan-
dard deviations of aggression scores. When mean and stan-
dard deviation were not reported or unavailable in the original
paper, authors were approached by email (Björkqvist et al.
1994), and asked to provide statistical information (i.e., F
and p values) necessary to calculate effect sizes. For the as-
sessment of heterogeneity, we used the Q-statistic and the I2
index. The latter indicates the proportion of the observed var-
iance that reflects real differences in effect size. It is expressed
as a percentage (0–100) with 0% indicating no heterogeneity,











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































25% indicating low heterogeneity, 50% indicating moderate
heterogeneity, and 75% suggesting high heterogeneity
(Higgins et al. 2003) respectively. Additionally, we used
Duval and Tweedie’s (2000) trim and fill method, and
Orwin’s (1983) fail-safe N to assess publication bias. The trim
and fill method (Duval and Tweedie 2000) screens for missing
studies and adjusts the effect size by trimming the asymmetric
studies and filling a funnel plot symmetrically. Orwin’s
(1983) fail-safe N quantifies the number of studies required
to bring the observed effect size down to a chosen “trivial”
estimate (Hedges and Olkin 2014). In the current meta-analy-
sis, we set the “trivial” estimate to g of 0.05.
The quality of each included study was assessed using the
Cochrane risk of bias tool (Higgins et al. 2003). The protocol
for the meta-analysis was pre-registered in PROSPERO (CRD
42019117834). The literature search, coding of variables, and
reporting were conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) procedure (Moher et al. 2009). The meta-analysis
and the meta-regression were performed using the
Comprehensive Meta-Analysis version 3.3.070 (Borenstein
et al. 2014).
Results
Literature screening and selection
From an initial pool of 30,407 hits, 18,988 records remained
after removal of duplicates (k = 3772) and gray literature (k =
7649) during initial identification and screening. Of this pool,
18,752 were removed after eligibility screening by title and
abstract leaving 238 records for further evaluation. After
screening the 238 full-text records, 12 studies were finally
included. Figure 1 presents the literature search and selection
process.
Description of included studies
Of the twelve included studies, publication year ranged from
1992 (Anderson et al. 1992) to 2017 (Carré et al. 2017; Cueva
et al. 2017; Panagiotidis et al. 2017). Four of the studies were
conducted in the USA (Pope et al. 2000; Su et al. 1993;
Tricker et al. 1996; Yates et al. 1999), four in the UK
(Anderson et al. 1992; Cueva et al. 2017; O’Connor et al.
2002, 2004), and one each in Germany (Panagiotidis et al.
2017), Finland (Björkqvist et al. 1994), Ireland (Dreher et al.
2016), and Canada (Carré et al. 2017). We received clarifica-
tion and data from some authors (Björkqvist et al. 1994; Carré
et al. 2017; Cueva et al. 2017; Dreher et al. 2016; O’Connor
et al. 2004). (See Table 1.)
All the included studies comprised placebo-controlled ran-


















































































































































































































































































































































































































































































































































































































































































(Anderson et al. 1992) and 11 were double-blinded.
Addi t ional ly, six studies were crossover s tudies
(Anderson et al. 1992; Cueva et al. 2017; O’Connor et al.
2004; Pope et al. 2000; Su et al. 1993; Yates et al. 1999)
whereas five were based on a between-subject design
(Björkqvist et al. 1994; Carré et al. 2017; Dreher et al.
2016; O’Connor et al. 2002; Panagiotidis et al. 2017;
Tricker et al. 1996). The studies included a total of 562
healthy male (females: n = 0) participants. Participants’
ages ranged from 18 (Su et al. 1993) to 49 (Carré et al.
2017) with a grand mean of 25.83 (SD = 3.80).
Testosterone enanthate was administered in four studies
(Anderson et al. 1992; Dreher et al. 2016; O’Connor et al.
2002; Tricker et al. 1996) and two studies administered tes-
tosterone cypionate (Pope et al. 2000; Yates et al. 1999). In
addition, two studies administered testosterone undecanoate
(Björkqvist et al. 1994; O’Connor et al. 2004), and three stud-
ies administered testosterone gel (Carré et al. 2017; Cueva
et al. 2017; Panagiotidis et al. 2017) whereas one study ad-
ministered methyltestosterone (Su et al. 1993). AAS doses
ranged from a one-time application of 50 mg of testosterone
gel (Panagiotidis et al. 2017) to a one-time injection of
1000 mg of testosterone undecanoate (O’Connor et al.
2004), and a cumulative injection of 7000 mg of testosterone
cypionate over a 14-week period (Yates et al. 1999). When
various doses of AAS were used in one study, we used results
from the highest dose for calculating the effect size.
Aggression was assessed by self-reports (Anderson et al.
1992; Björkqvist et al. 1994; Carré et al. 2017; Cueva et al.
2017; Dreher et al. 2016; O’Connor et al. 2002, 2004;
Panagiotidis et al. 2017; Pope et al. 2000; Su et al. 1993;
Tricker et al. 1996; Yates et al. 1999), observer-reports
(O’Connor et al. 2004; Tricker et al. 1996; Su et al. 1993;
Yates et al. 1999), and behavioral aggression measures
(Carré et al. 2017; Pope et al. 2000). The Buss-Perry
Aggression Questionnaire (Buss and Perry 1992) was used
in three studies (O’Connor et al. 2002, 2004; Pope et al.
2000), and three studies (O’Connor et al. 2002, 2004; Yates
et al. 1999) used the Buss-Durkee Hostility Inventory (Buss
and Durkee 1957), two studies (Carré et al. 2017; Pope et al.
2000) used the Point Subtraction Aggression Paradigm
(Cherek et al. 1996), and three studies (Dreher et al. 2016;
O’Connor et al. 2002, 2004) used the Profile of Mood States
(McNair et al. 1992) with two out of these three studies
(O’Connor et al. 2002, 2004) additionally using the
Aggression Provocation Questionnaire (O’Connor et al.
2001).
Additionally, the Self-Estimated Mood Checklist
(Lindman 1985) was used in one study (Björkqvist et al.
1994), and one study (Panagiotidis et al. 2017) used the
Technical Provocation Paradigm (Panagiotidis et al. 2017)
and emotional self-ratings (Schneider et al. 1994).
Moreover, two studies (Cueva et al. 2017; Su et al. 1993) used
visual analogue scales (Cline et al. 1992; Norris 1971), one
study (Tricker et al. 1996) used the Multi-Dimensional Anger
Inventory (Siegel 1986), and one study (Anderson et al. 1992)
used daily ratings of irritability, readiness to fight, and being
easily angered. 10 studies (Anderson et al. 1992; Carré et al.
2017; Cueva et al. 2017; Dreher et al. 2016; O’Connor et al.
2002, 2004; Panagiotidis et al. 2017; Pope et al. 2000; Tricker
et al. 1996; Yates et al. 1999) reported no significant effect of
AAS administration on aggression. In addition, one study (Su
et al. 1993) found a positive effect of AAS administration on
aggression (p < .05), whereas one study (Björkqvist et al.
1994) reported a negative effect of AAS administration on
aggression (p < .01).
Table 2 Mean baseline and post-
administration levels of placebo
and testosterone for each study
(nmol/L)





Anderson 1992 19.20 33.10 17.70 28.80
Björkqvist 1994 - - - -
Carré 2017 18.38 19.07 19.07 30.16
Cueva 2017 1.04 1.04 .69 10.05
Dreher 2016 20.46 20.44 21.06 66.08
O’Connor 2002 20.10 20.0 21.70 38.42
O’Connor 2004 20.30 20.30 20.70 37.50
Panagiotidis 2017 16.99 15.0 16.62 21.20
Pope 2000 16.30 18.40 17.40 76.00
Su 1993 - - - -
Tricker 1996 18.60 19.40 16.10 76.90
Yates 1999 20.82 19.08 20.82 73.73
Psychopharmacology
Risk of bias
The two authors disagreed once on the random sequence gen-
eration dimension for all the included studies yielding a
Cohen’s kappa of .58 (Cohen 1988). All studies were evalu-
ated as having a high selection bias as there was no description
of the randomization method or concealed allocation process.
In addition, all studies were evaluated as having high risks of
performance and detection bias as the effectiveness of
blinding was not tested. Moreover, all studies had a low risk
of attrition bias as there was sufficient reporting and handling
of attrition and exclusion. Furthermore, except for one study
that did not present means and standard deviations or inferen-
tial indices (Björkqvist et al. 1994), we evaluated all studies as
having low reporting bias. Figure 2 depicts the risk of bias of
the included studies.
Effect of AAS administration on self-reported
aggression
Of the twelve included studies, one study (Björkqvist et al.
1994) did not overlap with the 95% CI of the overall pooled
effect size. Exclusion of this outlier resulted in a mean and
significant random-effects size of g = 0.171 (95% CI:
0.029–0.312, k = 11, p = .018), and there was no significant
heterogeneity between the included studies (I2 = 0.000,Q =
8.891, p = .542). The effect sizes and associated 95% con-
fidence intervals are presented in Fig. 3.
The overall random-effects of AAS administration on self-
reported aggression, including the outlier (Björkqvist et al.
1994), was not significant (g = 0.081, 95% CI: −0.111–
0.273, p = .408). (See Supplementary Figure 1.) When
adjusting for publication bias using Duval and Tweedie’s trim
and fill method, the overall result (k = 12) turned out non-
significant (g = 0.170, 95% CI: 0.029–0.312, p = .890). (See
Supplementary Figure 2.) Results from Orwin’s fail-safe N
analysis indicated that 27 studies with an effect size of zero
would be needed to bring Hedges’ g below 0.05.
Effect of long-term AAS administration
on self-reported aggression
The random-effects of administering AAS over longer periods
(3 days to 14 weeks) on self-reported aggression under a
random-effects model was g = 0.100 (95% CI:−0.079–
0.278, p = .273). There was no significant heterogeneity
across studies in terms of effect sizes (I2 = 5.286, Q = 6.335,
p = .321). (See Fig. 4.)
Effect of acute AAS administration on self-reported
aggression
Under a fixed-effect model, the effect of acute administration
of AAS on self-reported aggression was g = 0.291 (95% CI:
0.014–0.524, p = .014, Q =.867, p = .833 ). (See Fig. 5.)
Effect of AAS dose on self-reported aggression
AAS dose (mg) was not associated with self-reported aggres-
sion in a random-effects meta-regression model (B = 0.000,
SE = 0.000 (95% CI: −0.000–0.000), p = .096).
Effect of high-dose AAS administration on self-
reported aggression
The mean effect of higher doses (over 500 mg) of AAS on
self-reported aggression under a fixed-effect model was non-
significant (g = 0.191; 95% CI: −0.007–0.388, p = .059, Q =
1.399, p = .844). (See Fig. 6.)Fig. 2 Estimated risk of bias of the included studies
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Effect of AAS administration on observer-reported
aggression
The overall fixed-effect of AAS administration on aggression
based on observer ratings resulted in an effect size of g = 0.157
(95% CI: −0.026–0.581, p = .469, Q = .249, p = .833). The
effect sizes and associated 95% confidence intervals for each
study are presented in Fig. 7.
Discussion
The present systematic review and meta-analysis of eleven
studies (Anderson et al. 1992; Carré et al. 2017; Cueva et al.
2017; Dreher et al. 2016; O’Connor et al. 2002, 2004;
Panagiotidis et al. 2017; Pope et al. 2000; Su et al. 1993;
Tricker et al. 1996; Yates et al. 1999), after excluding an
outlier (Björkqvist et al. 1994), indicates that AAS adminis-
tration is associated with an increase in self-reported aggres-
sion, albeit small, among healthy males in RCTs. This finding
is consistent with the results of a recent meta-analysis
(Geniole et al. 2020) indicating that testosterone administra-
tion has a small and positive correlation with aggression in
males. Relatedly, our finding that acute AAS administration
has a positive effect on self-reported aggression is consistent
with evidence that acute increases in testosterone have a pos-
itive correlation with aggression (Geniole et al. 2020).
The present study is the first comprehensive systematic
review and meta-analytic investigation of the effect of AAS
administration and aggression in healthy males in RCTs.
However, our results should be interpreted with caution.
Firstly, a meta-regression examining dosage as a moderator
of the identified effect of AAS on self-reported aggression
turned out not significant. Similarly, we did neither detect an
effect of AAS administration on observer-reported aggression
nor for the effects of long-term (3 days to 14 weeks) and high-
dose AAS administration on self-reported aggression. Also, as
noted previously, only healthy males were examined in the
included RCTs and the duration and doses used in the twelve
RCTs deviate from the prolonged use of high-dose cycles
consisting of the ingestion of supraphysiologic doses of dif-
ferent types of AAS per week over several months (Kanayama
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Anderson 1992 -0.349 0.302 0.091 -0.940 0.242 -1.157 0.247
Carre 2017 0.393 0.188 0.035 0.025 0.762 2.094 0.036
Cueva 2017 -0.346 0.321 0.103 -0.975 0.282 -1.081 0.280
Dreher 2016 0.072 0.310 0.096 -0.537 0.680 0.231 0.817
O'Connor 2002 0.299 0.361 0.130 -0.408 1.006 0.829 0.407
O'Connor 2004 0.218 0.164 0.027 -0.104 0.540 1.327 0.185
Panagiotidis 2017 0.268 0.195 0.038 -0.114 0.650 1.375 0.169
Pope 2000 0.000 0.273 0.075 -0.535 0.535 0.000 1.000
Su 1993 0.299 0.184 0.034 -0.062 0.660 1.622 0.105
Tricker 1996 0.313 0.415 0.172 -0.500 1.126 0.755 0.450
Yates 1999 0.000 0.284 0.081 -0.556 0.556 0.000 1.000
0.171 0.072 0.005 0.029 0.312 2.365 0.018
-1.00 -0.50 0.00 0.50 1.00
Negative effect Positive effect
Overall
Fig. 3 The effect (random-effects model) of AAS administration on self-reported aggression
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Anderson 1992 -0.349 0.302 0.091 -0.940 0.242 -1.157 0.247
Cueva 2017 -0.339 0.320 0.103 -0.967 0.289 -1.058 0.290
O'Connor 2002 0.299 0.361 0.130 -0.408 1.006 0.829 0.407
O'Connor 2004 0.218 0.164 0.027 -0.104 0.540 1.327 0.185
Pope 2000 0.000 0.273 0.075 -0.535 0.535 0.000 1.000
Su 1993 0.299 0.184 0.034 -0.062 0.660 1.622 0.105
Yates 1999 0.000 0.284 0.081 -0.556 0.556 0.000 1.000
0.094 0.095 0.009 -0.091 0.279 0.993 0.321
-1.00 -0.50 0.00 0.50 1.00
Negative effect Positive effect
Overall
Fig. 4 The effect (random-effects model) of administering AAS over longer periods on self-reported aggression
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et al. 2013) often reported by users in ecologically valid set-
tings. In one study, the reported weekly AAS dose ranged
from 125 to 7000 (mean = 1278) mg per week over an average
of 9.1 years (Bjørnebekk et al. 2017). In another recent study,
it was shown that an AAS cycle usually comprises the inges-
tion of five different AAS with an average dose of 901 mg per
week for a typical duration of 13 weeks (Smit et al. 2020b). In
the present meta-analysis, the highest dose administered was a
one-time injection of 1000 mg of testosterone undecanoate
(O’Connor et al. 2004) and a cumulative injection of
7000 mg of testosterone cypionate over a 14-week period
(Yates et al. 1999). Inferably, AAS doses and duration of
administration in the RCTs included in our meta-analysis are
far lower than the actual doses reported by AAS users
(Bjørnebekk et al. 2017; Kanayama et al. 2013).
Similarly, besides the administration of methyltestosterone
in one study (Su et al. 1993), fluoxymesterone, oxymetholone,
and trenbolone that are anecdotally associated with increased
aggression in humans (Barker 1987; Llewellyn 2011) were
not administered in the RCTs included in the present review.
Moreover, testosterone undecanoate administered in two stud-
ies (Björkqvist et al. 1994; O’Connor et al. 2004) is a depot
with a very gradual decay and long half-life leading to rela-
tively stable testosterone levels over a prolonged period of
time (Hirschhäuser et al. 1975). Hence, discrepancies in
AAS doses, type, duration of use, and half-life between the
AAS in the RCTs and naturalistic contexts should be noted
when interpreting our findings.
In addition, evidence from cross-sectional studies indicates
that polypharmacy and stacking (Sagoe et al. 2015; Salinas
et al. 2019) may account for increased aggression amongAAS
users (Lundholm et al. 2015). The absence of polypharmacy
in the RCTs included in our meta-analysis may also explain
the discrepancy between findings from RCTs and those re-
ported in more ecologically valid contexts. Other potential
confounding factors include small sample sizes and lack of a
priori power analyses, diversity in aggression measures, risk
of bias (selection, performance, and detection biases), diversi-
ty in route of administrating AAS (injecting, transdermally),
diversity in time gap between AAS administration, incom-
plete data reporting, and sampling of only males in included
RCTs.
Moreover, the inclusion of only healthy volunteers in
the RCTs may have precluded vulnerable subjects from
participating which may have led to the underestimation
of the effects of AAS administration on aggression.
Sampling is important with evidence that testosterone in-
creases aggression in men with certain personality profiles
especially among those with fewer cytosine-adenine-
guanine repeats in exon 1 of the androgen receptor gene
(Geniole et al. 2019). The importance of sampling is fur-
ther evidenced in that, apart from bodybuilders and com-
petitive athletes, a large portion of non-experimental re-
search linking AAS use with aggression has been con-
ducted among subgroups associated with aggression such
as drug users, offenders, and prisoners (Lundholm et al.
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Carre 2017 0.393 0.188 0.035 0.025 0.762 2.094 0.036
Dreher 2016 0.060 0.310 0.096 -0.548 0.669 0.194 0.846
Panagiotidis 2017 0.268 0.195 0.038 -0.114 0.650 1.375 0.169
Tricker 1996 0.313 0.415 0.172 -0.500 1.126 0.755 0.450
0.291 0.119 0.014 0.059 0.524 2.453 0.014
-1.00 -0.50 0.00 0.50 1.00
Negative effect Positive effect
Overall
Fig. 5 The effect (fixed-effect model) of acute AAS administration on self-reported aggression
Study name Statistics for each study Dose Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
O'Connor 2004 0.218 0.164 0.027 -0.104 0.540 1.327 0.185 1000
Pope 2000 0.000 0.273 0.075 -0.535 0.535 0.000 1.000 600
Su 1993 0.299 0.184 0.034 -0.062 0.660 1.622 0.105 240
Tricker 1996 0.313 0.415 0.172 -0.500 1.126 0.755 0.450 600
Yates 1999 0.000 0.284 0.081 -0.556 0.556 0.000 1.000 500
0.191 0.101 0.010 -0.007 0.388 1.887 0.059
-1.00 -0.50 0.00 0.50 1.00
Negative effect Positive effect
Overall
Fig. 6 The effect (fixed-effect model) of administering higher (over 500 mg) doses of AAS on self-reported aggression
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2010; Pope et al. 1996), as well as policemen, doormen,
and nightclub bouncers (Hoberman 2017; Midgley et al.
2001). Future researchers considering the aforementioned
factors may conduct more ecologically valid RCTs (e.g.,
by using dosages and duration of use similar to those by
real AAS users) to better elucidate the effect of AAS
administration on aggression in humans. Furthermore,
more studies should explore factors of AAS administra-
tion (e.g., type of AAS, duration of use, premorbid func-
tioning, and genetics) that might moderate the effects of
AAS on aggression.
Conclusions
The present systematic review and meta-analysis provide
evidence for an increase, although small, in self-reported
aggression in healthy males following AAS administration
in RCTs. Moreover, when restricting the analysis to the
effects of acute AAS administration on self-reported ag-
gression, we found a significant effect. We also identified
important limitations of the RCTs on issues such as non-
ecological doses, lack of personality and polypharmacy
controls, small sample sizes, risk of bias, short study dura-
tion, and the inclusion of only healthy males. While future
RCTs adjusting for the above factors may contribute better
to contemporary understanding of the effect of AAS admin-
istration on aggression in humans, the present study pro-
vides an important foundation for addressing this important
public health issue. As the appreciation of the heterogeneity
of AAS use matures, there is a need to identify the role that
AAS plays in aggression and violence and what may be
attributed to the set and setting of their use.
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